Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

• Published in: Breast cancer research : BCR Vol. 26; no. 1; p. 35
• Main Authors: Smoots, Stephen G, Schreiber, Anna R, Jackson, Marilyn M, Bagby, Stacey M, Dominguez, Adrian T A, Dus, Evan D, Binns, Cameron A, MacBeth, Morgan, Whitty, Phaedra A, Diamond, Jennifer R, Pitts, Todd M
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.03.2024; BioMed Central; BMC
• Subjects: Annexin V; Apoptosis; Autophagy; Bioavailability; Biotechnology industry; Breast cancer; Cancer; Cancer therapies; Cell cycle; Cell division; Cell fate; Chemoresistance; Chemotherapy; DNA damage; DNA repair; Doxorubicin; Flow cytometry; Genes; Growth inhibition; Histone deacetylase; Histone deacetylase inhibitor; Immunoblotting; Kinases; Mutation; Prognosis; Proteins; Senescence; Toxicity; Triple-negative breast cancer; Tumor proteins; Tumors; β-Galactosidase; United States; United States > US; Doxorubicin; Histone deacetylase inhibitor; Triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with a poor prognosis. Doxorubicin is part of standard curative therapy for TNBC, but chemotherapy resistance remains an important clinical challenge. Bocodepsin (OKI-179) is a small molecule class I histone deacetylase (HDA...